Innovative Medicine

Black Americans are up to four times more likely to have a PAD-related amputation,1 largely due to greater delays in care2 and less access to quality vascular care1 Save Legs. Change Lives.™ aims to reach more than 10 million Black Americans over the multi-year initiative

More than 50 presentations across hematologic malignancies and diseases demonstrate Janssen’s commitment to innovation and transforming the treatment of blood cancers across lines of therapy and patient types

Previously reported results from QUASAR Induction Study 1 showed clinical response was achieved by approximately 60 percent of patients at week 12 Study results presented at 2022 American College of Gastroenterology Annual Meeting showed that continued treatment with subcutaneous TREMFYA allowed a mean of 52.1 percent of IV TREMFYA week 12 clinical nonresponders to achieve clinical response at week 24

55.2 percent of induction responder patients treated with STELARA at the start of maintenance were in symptomatic remission approximately four years later (at week 200), 96.4 percent without corticosteroids Overall, 79.1 percent of patients treated with STELARA in the long-term extension (LTE) who were receiving corticosteroids at maintenance baseline were no longer receiving corticosteroids by week 200

Results from Phase 1/2 MGT009 study demonstrate safety profile of investigational gene therapy botaretigene sparoparvovec (AAV-RPGR) and suggest sustained vision improvement in patients with X-linked retinitis pigmentosa (XLRP) Data from a separate Phase 1 study show all three doses of investigational gene therapy JNJ-1887 met the primary endpoint for safety in adults with geographic atrophy (GA)

GUIDE week 28 data demonstrate psoriasis patients treated with guselkumab ≤2 years after disease onset (versus >2 years) are more likely to achieve super-respondera status (complete skin clearanceb at week 20 through week 28) Late-breaking week 68 data suggest these super responders could maintain long-term disease control (low disease activity) with an extended dose interval

Data featured in plenary session at the 19th International Myeloma Society Annual Meeting

IMBRUVICA® is now the only BTKi with 12 FDA approvals across seven indications, including five hematologic cancers and cGVHD

Teclistamab, an off-the-shelf (ready to use) subcutaneously administered therapy, induced deep and rapid responses in triple-class exposed patients with relapsed and refractory multiple myeloma[1]